You have accessJournal of UrologyProstate Cancer: Markers I1 Apr 2017MP28-17 IMMUNOHISTOCHEMICAL STAINING OF ERG AND SOX9 AS POTENTIAL BIOMARKERS OF DOCETAXEL RESPONSE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER Song Wan, Ghee Young Kwon, Jeong Hoon Kim, Joung Eun Lim, Young Hyo Choi, Hyun Woo Chung, Chung Un Lee, Jun Phil Na, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Han Yong Choi, and Hyun Moo Lee Song WanSong Wan More articles by this author , Ghee Young KwonGhee Young Kwon More articles by this author , Jeong Hoon KimJeong Hoon Kim More articles by this author , Joung Eun LimJoung Eun Lim More articles by this author , Young Hyo ChoiYoung Hyo Choi More articles by this author , Hyun Woo ChungHyun Woo Chung More articles by this author , Chung Un LeeChung Un Lee More articles by this author , Jun Phil NaJun Phil Na More articles by this author , Hwang Gyun JeonHwang Gyun Jeon More articles by this author , Byong Chang JeongByong Chang Jeong More articles by this author , Seong Il SeoSeong Il Seo More articles by this author , Seong Soo JeonSeong Soo Jeon More articles by this author , Han Yong ChoiHan Yong Choi More articles by this author , and Hyun Moo LeeHyun Moo Lee More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.830AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Docetaxel-based chemotherapy is recommended as first-line standard of care for metastatic castration-resistant prostate cancer (mCRPC). However, most of the patients developed treatment resistance and experienced treatment-related toxicity. Therefore, we constructed tissue microarrays using prostate biopsy samples and carried out immunohistochemistry (IHC) analyses to evaluate the clinical utility of ERG and SOX9 as potential biomarkers of docetaxel response in mCRPC patients. METHODS We reviewed 71 patients diagnosed with mCRPC and treated with docetaxel (75mg/m2 intravenously, every 3 weeks) between 2001 and 2013. We evaluated the prostate specific antigen (PSA) response rate, PSA progression-free survival (PSA-PFS), clinical/radiologic PFS (C/R-PFS) and the overall survival (OS) based on the recommendations of the Prostate Cancer Working Group 2. The intensities of ERG and SOX9 expression in tumor cells were scored using a four-tiered grading system. A sample with more than 5% of total stained area scoring 2+ or 3+ in intensity was considered to be positive. Kaplan-Meier survival curves were constructed to illustrate the PSA-PFS, C/R-PFS and OS. Multivariate Cox proportional hazard models were utilized to estimate associations between the PSA-PFS, C/R-PFS, OS and risk factors of interest. RESULTS ERG and SOX9 were found in 13 (18.3%) and 62 (87.3%) patients, respectively. ERG-positive had lower PSA response rates than negative (15.4% vs 62.1%, p = 0.004), and SOX9 showed a same trend (46.8% vs 100.0%, p = 0.003). ERG positivity correlated with a lower PSA-PFS (3.2 mos vs 7.4 mos, p < 0.001), C/R-PFS (3.8 mos vs 9.0 mos, p < 0.001) and OS (10.8 mos vs 21.4 mos, p < 0.001). SOX9 positivity also showed a lower PSA-PFS, C/R-PFS and OS (p =0.006, p =0.012 and p =0.023, respectively). On multivariate analysis, ERG positivity was a significant risk factor for a lower PSA-PFS (p < 0.001, hazard ratio (HR): 6.00, 95% confidence interval (CI): 2.96-12.16), C/R-PFS (p < 0.001, HR: 5.50, 95% CI: 2.68-11.29) and OS (p = 0.001, HR: 3.31, 95% CI: 1.66-6.64). In addition, SOX9 was also a significant risk factor for a decreased PSA-PFS (p = 0.018, HR: 2.75, 95% CI: 1.19-6.32), C/R-PFS (p = 0.025, HR: 2.44, 95% CI: 1.12-5.30) and OS (p = 0.047, HR: 4.30, 95% CI: 1.02-18.16). CONCLUSIONS IHC-detected ERG and SOX9 expression is significantly associated with lower PSA-PFS, C/R-PFS and OS in patients with mCRPC treated with docetaxel. They could be used as potential biomarkers for prediction to docetaxel treatment in mCRPC patients. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e345 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Song Wan More articles by this author Ghee Young Kwon More articles by this author Jeong Hoon Kim More articles by this author Joung Eun Lim More articles by this author Young Hyo Choi More articles by this author Hyun Woo Chung More articles by this author Chung Un Lee More articles by this author Jun Phil Na More articles by this author Hwang Gyun Jeon More articles by this author Byong Chang Jeong More articles by this author Seong Il Seo More articles by this author Seong Soo Jeon More articles by this author Han Yong Choi More articles by this author Hyun Moo Lee More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...